Drugs / BH-30236
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06501196 | Jun 2024 → Jun 2026 overdue | acute myeloid leukemia, myelodysplastic syndrome, premalignant hematological system disease | BlossomHill Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BH-30236 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06501196 ↗ |
| Action | Inhibit | “the orally available CDC-Like Kinase (CLK) Inhibitor, BH-30236” NCT06501196 ↗ |
| Route | Oral | “Participants will take BH-30236 tablets orally depending on their dose level assignment.” NCT06501196 ↗ |